拉迪克斯·阿斯特拉加利及其代表性提取物用于糖尿病病:有效性和分子机制
Hui-Zhong Xue1, Yu Chen2, Shi-Dong Wang3
1The First Clinical Medical School Beijing University of Chinese Medicine, Beijing, China 100700.
Journal of diabetes research
|September 23, 2024
概括
拉迪克斯阿斯特拉加利 (RA) 通过改善功能和减少蛋白尿,有效治疗糖尿病病 (DN). 它的机制涉及抗氧化,抗炎和抗纤维路径,由传统中医原则支持.
科学领域:
- 药理学和中国传统医学 (TCM)
背景情况:
- 糖尿病病 (DN) 是糖尿病 (DM) 的一个严重的微血管并发症.
- 拉迪克斯·阿斯特拉加利 (RA) 是来自Leguminosae家族的一种草药,在TCM中广泛用于DN治疗.
- 临床和实验研究都支持RA在管理DN方面的有效性.
研究的目的:
- 审查Radix Astragali (RA) 在治疗糖尿病病 (DN) 的临床有效性.
- 阐明RA对DN的治疗作用背后的药理机制.
- 探索TCM理论基础,用于RA在DN中的应用.
主要方法:
- 对糖尿病病 (DN) 治疗Radix Astragali (RA) 的临床研究和实验研究的综述.
- 分析RA向的分子通路,包括氧化应激,内质网膜应激,自,炎症和纤维化.
- 检查与DN治疗中RA相关的传统用途和TCM理论.
主要成果:
- RA及其提取物在减少蛋白尿和改善DN中的功能方面表现出有效性.
- 肌痛性关节炎改善脏的组织病理变化,例如球底膜加厚和细胞损伤.
- 关键机制包括对Nrf2/ARE,PPARγ-Klotho-FoxO1,PERK-ATF4-CHOP,SIRT1/NF-κB,AMPK,IL33/ST2,TGF-β1/Smads以及MAPK信号通路的调节.
结论:
- 拉迪克斯阿斯特拉加利 (RA) 是糖尿病病 (DN) 的有前途的治疗药物.
- 其益处归因于多重向的药理作用,包括抗氧化,抗炎和抗纤维素作用.
- 在DN中RA的传统使用得到了现代药理学证据和TCM理论的支持.
更多相关视频
相关概念视频
01:16Antihypertensive Drugs: Action of Diuretics
629
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
629
01:23Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167